Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations.

Thrombosis and haemostasis - 1 Jun 2006

Hussein Mohamad A

Abstract excerpt

Deep vein thrombosis and its lethal complication pulmonary embolism are manifestations of venous thromboembolism (VTE), which is typically associated with cancer and recent major surgery. Certain solid tumors and hematologic malignancies impose an inherently elevated risk of VTE that is compounde...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Aspirin
Share to Immunologic Factors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Multiple Myeloma

Share to Prothrombin

Share to Risk Reduction Behavior

Share to Venous Thrombosis

Share to Warfarin

Source

Identifiers

PMID: 16732369
DOI: 10.1160/TH06-02-0080

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-16732369-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations.PMID 16732369Read ↗

A review of the venous thrombotic issues associated with multiple myeloma.Semantic proximity Read ↗

Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis.Semantic proximity Read ↗

Prevention of recurrent thromboembolism in myeloproliferative neoplasms: review of literature and focus on direct oral anticoagulants.Semantic proximity Read ↗

Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens.Semantic proximity Read ↗

Thrombotic and bleeding complications in classical myeloproliferative neoplasms.Semantic proximity Read ↗

Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.Semantic proximity Read ↗

Two cases of proteasome inhibitors related thrombotic microangiopathies and literature reviewSemantic proximity Read ↗

Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide.Semantic proximity Read ↗

[Analysis of risk factors for thromboembolism in patients with JAK2V617F gene mutation positive myeloproliferative neoplasms].Semantic proximity Read ↗

Consensus statement of the Spanish Society of Internal Medicine and the Spanish Society of Medical Oncology on secondary thromboprophylaxis in patients with cancer.Semantic proximity Read ↗

Risk factors of thrombosis in a cohort of 206 patients with BCR-ABL1 negative myeloproliferative neoplasms.Semantic proximity Read ↗

Thrombosis among 1537 patients with JAK2V617F -mutated myeloproliferative neoplasms: Risk factors and development of a predictive model.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.